Φορτώνει......
Into the Clinic With Nivolumab and Pembrolizumab
In 2015, the US Food and Drug Administration approved the use of nivolumab for treatment of squamous and nonsquamous non-small cell lung cancer (NSCLC) and pembrolizumab for use in patients with NSCLC tumors that express PD-L1. This commentary discusses issues with these two drugs relative to best p...
Αποθηκεύτηκε σε:
| Τόπος έκδοσης: | Oncologist |
|---|---|
| Κύριοι συγγραφείς: | , |
| Μορφή: | Artigo |
| Γλώσσα: | Inglês |
| Έκδοση: |
AlphaMed Press
2016
|
| Θέματα: | |
| Διαθέσιμο Online: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4861376/ https://ncbi.nlm.nih.gov/pubmed/27026678 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1634/theoncologist.2016-0099 |
| Ετικέτες: |
Προσθήκη ετικέτας
Δεν υπάρχουν, Καταχωρήστε ετικέτα πρώτοι!
|